Swethajit Biswas

Shet joined CDR-Life in August 2022. Prior to joining CDR-Life, he was a Development Leader for MAGE-A4+ autologous cell therapies at Adaptimmune Therapeutics plc, progressing afamitresgene autoleucel through an accelerated approval submission pathway. Before that, Shet was a Clinical Director in oncology drug development at GlaxoSmithKline (GSK) Oncology, U.K., serving as the clinical lead for the company’s BCMA-targeting multiple myeloma program with multiple trials across all phases of development.

He previously worked as a National Health Service (NHS) Consultant with clinical expertise in teenage cancer medicine, sarcoma, lymphomas and brain tumors at two university teaching hospitals in the UK. He also held an academic position as a Clinical Senior Lecturer in medical oncology at Newcastle University’s Northern Institute for Cancer Research (NICR) from 2009 to 2013.

Shet received his medical degree from Sheffield University Medical School and his DPhil from the University of Oxford. He became an elected Fellow of the Royal College of Physicians (FRCP), London, in 2020.